首页|Astragalus polysaccharides can regulate cytokine and P-glycoprotein expression in H22 tumor-bearing mice

Astragalus polysaccharides can regulate cytokine and P-glycoprotein expression in H22 tumor-bearing mice

扫码查看
AIM:To investigate the adjunct anticancer effect of Astragalus polysaccharides in H22 tumor-bearing mice.METHODS:To establish a solid tumor model,5.0 ×106/mL H22 hepatoma cells were inoculated subcutaneously into the right armpit region of Kunming mice (6-12wk old,18-22 g).When the tumors reached a size of 100 mm3,the animals were treated as indicated,and the mice were randomly assigned to seven groups (n=10 each).After ten days of treatment,blood samples were collected from mouse eyes,and serum was harvested by centrifugation.Mice were sacrificed,and the whole body,tumor,spleen and thymus were weighed immediately.The rate of tumor inhibition and organ indexes were calculated.The expression levels of serum cytokines,P-glycoprotein (P-GP) and multidrug resistance (MDR) 1 mRNA in tumor tissues were detected using enzyme-linked immunosorbent assay,Western blotting,and quantitative myeloid-derived suppressor cells reverse transcription-polymerase chain reaction,respectively.RESULTS:The tumor inhibition rates in the treatment groups of Adriamycin (ADM) + Astragalus polysaccharides (APS) (50 mg/kg),ADM + APS (100 mg/kg),and ADM + APS (200 mg/kg) were significantly higher than in the ADM group (72.88% vs 60.36%,P =0.013;73.40% vs 60.36%,P =0.010; 77.57% vs 60.36%,P =0.001).The spleen indexes of the above groups were also significantly higher than in the ADM group (0.65 ± 0.22 vs 0.39 ± 0.17,P =0.023; 0.62 ± 0.34 vs0.39 ± 0.17,P =0.022; 0.67 ± 0.20 vs 0.39 ± 0.17,P=0.012),and the thymus indexes of the ADM + APS (100 mg/kg) and ADM + APS (200 mg/kg) groups were significantly higher than in the ADM group (0.20 ± 0.06vs 0.13 ±-0.04,P =0.029; 0.47 ± 0.12 vs 0.13 ± 0.04,P =0.000).APS was found to exert a synergistic antitumor effect with ADM and to alleviate the decrease in the sizes of the spleen and thymus induced by AMD.The expression of interleukin-1α (IL-1α),IL-2,IL-6,and tumor necrosis factor-α (TNF-α) was significantly higher in the ADM + APS (50 mg/kg),ADM + APS (100mg/kg) and ADM + APS (200 mg/kg) groups than in the ADM group; and IL-10 was significantly lower in the above groups than in the ADM group.APS could increase IL-1α,IL-2,IL-6,and TNF-α expression and decrease IL-10 levels.Compared with the ADM group,APS treatment at a dose of 50-200 mg/kg could downregulate MDR1 mRNA expression in a dose-dependent manner (0.48 ± 0.13 vs 4.26 ± 1.51,P =0.000; 0.36± 0.03 vs 4.26 ± 1.51,P =0.000; 0.21 ± 0.04 vs4.26 ± 1.51,P =0.000).The expression level of P-GP was significantly lower in the ADM + APS (200 mg/kg)group than in the ADM group (137.35 ± 9.20 mg/kg vs 282.19 ± 20.54 mg/kg,P =0.023).CONCLUSION:APS exerts a synergistic anti-tumor effect with ADM in H22 tumor-bearing mice.This may be related to its ability to enhance the expression of IL-1α,IL-2,IL-6,and TNF-α,decrease IL-10,and downregulate MDR1 mRNA and P-GP expression levels.

Astragalus polysaccharidesTumor inhibition rateCytokinesP-glycoproteinAdjunct anticancer

Qing-E Tian、Huan-De Li、Miao Yan、Hua-Lin Cai、Qin-You Tan、Wen-Yuan Zhang

展开 >

School of Pharmaceutical Sciences, Central South University, Changsha 410011, Hunan Province, China

Xiangtan Central Hospital, Xiangtan 411100, Hunan Province, China

Clinical Pharmacy and Pharmacology Research Institute, the Second Xiangya Hospital, Central South University, Changsha 410011, Hunan Province, China

2012

世界胃肠病学杂志(英文版)
太原消化病研治中心

世界胃肠病学杂志(英文版)

SCI
影响因子:1.001
ISSN:1007-9327
年,卷(期):2012.18(47)
  • 24
  • 36